FindTrial
Sign In

Comparison of intravenous and nebulised routes of dexmedetomidine as premedication on surgical field visualisation in functional endoscopic sinus surgeries : a randomised control trial

Comparison of intravenous and nebulised dexmedetomidine on surgical field visualisation in functional endoscopic sinus surgeries: a randomised control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052754
Enrollment
114
Registered
2023-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J01- Acute sinusitis Health Condition 2: J31- Chronic rhinitis, nasopharyngitisand pharyngitis Health Condition 3: J32- Chronic sinusitis Health Condition 4: O- Medical and Surgical Health Condition 5: J33- Nasal polyp Health Condition 6: J34- Other and unspecified disorders ofnose and nasal sinuses Health Condition 7: J30- Vasomotor and allergic rhinitis

Interventions

Intervention1: Intravenous Dexmedetomidine as premedication: dexmedetomidine at a dose of 1 microgram/ kilogram diluted in 100 ml normal saline once via intravenous route for 15 minutes over infusion

Sponsors

All India Institute of Medical Sciences, Bathinda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: American society of anaesthesiologists physical status 1 to 2 scheduled for elective functional endosocopic sinus surgeries under general anaesthesia

Exclusion criteria

Exclusion criteria: 1. Patients not giving consent 2. Patient with body mass index = 35 kg/m2. 3. Pregnant patients 4. Patients who are allergic to any study drug 5. Patients with moderate-severe cardiovascular, respiratory, renal or hepatic impairment. • Patients with anticipated difficult airway • Patients who are smokers (more than 10 pack-years) • Patients with bleeding diathesis • Patients taking any type of BP controlling drugs

Design outcomes

Primary

MeasureTime frame
Surgical field visualisationTimepoint: till the end of surgery—

Secondary

MeasureTime frame
Hemodynamic changes, post-operative sore throat, post- operative nausea & vomiting and sedative effect will be observedTimepoint: till 24 hours after the end of the surgery.—

Countries

India

Contacts

Public ContactDr Hemanthkumar

All India Institute of Medical Sciences, Bathinda

drm_gupta@yahoo.co.in8077754166

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026